Letter

Nature 446, 79-82 (1 March 2007) | doi:10.1038/nature05557; Received 4 August 2006; Accepted 27 December 2006; Published online 11 February 2007

Chemical rescue of cleft palate and midline defects in conditional GSK-3bold beta mice

Karen J. Liu1,2,6,7, Joseph R. Arron1,6,7, Kryn Stankunas3, Gerald R. Crabtree1,3,4 & Michael T. Longaker2,5

  1. The Department of Pathology,
  2. The Stanford Institute for Stem Cell Biology and Regenerative Medicine,
  3. Department of Developmental Biology,
  4. Howard Hughes Medical Institute, and the
  5. Division of Plastic and Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Palo Alto, California 94305, USA.
  6. Present addresses: Department of Craniofacial Development, King's College London, London SE1 9RT, UK (K.J.L.); Department of Immunology Diagnostics, Genentech, 1 DNA Way, South San Francisco, California 94080, USA (J.R.A.)
  7. These authors contributed equally to this work.

Correspondence to: Karen J. Liu1,2,6,7Michael T. Longaker2,5 Correspondence and requests for materials should be addressed to K.J.L. (Email: karen.liu@kcl.ac.uk) or M.T.L. (Email: longaker@stanford.edu).

Glycogen synthase kinase-3beta (GSK-3beta) has integral roles in a variety of biological processes, including development, diabetes, and the progression of Alzheimer's disease1, 2, 3, 4. As such, a thorough understanding of GSK-3beta function will have a broad impact on human biology and therapeutics. Because GSK-3beta interacts with many different pathways, its specific developmental roles remain unclear5. We have discovered a genetic requirement for GSK-3beta in midline development. Homozygous null mice display cleft palate, incomplete fusion of the ribs at the midline and bifid sternum as well as delayed sternal ossification. Using a chemically regulated allele of GSK-3beta (ref. 6), we have defined requirements for GSK-3beta activity during discrete temporal windows in palatogenesis and skeletogenesis. The rapamycin-dependent allele of GSK-3beta produces GSK-3beta fused to a tag, FRB* (FKBP/rapamycin binding), resulting in a rapidly destabilized chimaeric protein. In the absence of drug, GSK-3betaFRB*/FRB* mutants appear phenotypically identical to GSK-3beta-/- mutants. In the presence of drug, GSK-3betaFRB* is rapidly stabilized, restoring protein levels and activity6. Using this system, mutant phenotypes were rescued by restoring endogenous GSK-3beta activity during two distinct periods in gestation. This technology provides a powerful tool for defining windows of protein function during development.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

A hole in the head

Nature Genetics News and Views (01 Apr 2000)

Extra navigation

.

naturejobs

ADVERTISEMENT